Carbon monoxide and bile pigments: surprising mediators of vascular function
- PMID: 12553743
- DOI: 10.1191/1358863x02vm424ra
Carbon monoxide and bile pigments: surprising mediators of vascular function
Abstract
Heme oxygenase (HO) catalyzes the degradation of heme to CO, iron, and biliverdin. Biliverdin is subsequently metabolized to bilirubin by the enzyme biliverdin reductase. Although long considered irrelevant byproducts of heme catabolism, recent studies indicate that CO and the bile pigments biliverdin and bilirubin may play an important physiological role in the circulation. The release of CO by vascular cells may modulate blood flow and blood fluidity by inhibiting vasomotor tone, smooth muscle cell proliferation, and platelet aggregation. CO may also maintain the integrity of the vessel wall by directly blocking vascular cell apoptosis and by inhibiting the release of pro-apoptotic inflammatory cytokines from the vessel wall. These effects of CO are mediated via multiple pathways, including activation of soluble guanylate cyclase, potassium channels, p38 mitogen-activated protein kinase, or inhibition of cytochrome P450. In addition, the release of bile pigments may serve to sustain vascular homeostasis by protecting vascular cells from oxidative stress and by inhibiting the adhesion and infiltration of leukocytes into the vessel wall. Induction of HO-1 gene expression and the subsequent release of CO and bile pigments are observed in numerous vascular disorders and may provide an important adaptive mechanism to preserve homeostasis at sites of vascular injury. Thus, the HO-catalyzed formation of CO and bile pigments by vascular cells may function as a critical endogenous vasoprotective system. Moreover, pharmacological or genetic approaches targeting HO-1 to the vessel wall may represent a novel therapeutic approach in treating vascular disease.
Similar articles
-
Heme oxygenase-carbon monoxide signalling pathway in atherosclerosis: anti-atherogenic actions of bilirubin and carbon monoxide?Cardiovasc Res. 1999 Feb;41(2):385-94. doi: 10.1016/s0008-6363(98)00278-8. Cardiovasc Res. 1999. PMID: 10341838 Review.
-
[Heme oxygenase and carbon monoxide in the physiology and pathology of the cardiovascular system].Postepy Hig Med Dosw (Online). 2004 Mar 3;58:83-99. Postepy Hig Med Dosw (Online). 2004. PMID: 15069378 Review. Polish.
-
Carbon monoxide and vascular cell function (review).Int J Mol Med. 1998 Sep;2(3):255-62. doi: 10.3892/ijmm.2.3.255. Int J Mol Med. 1998. PMID: 9855696 Review.
-
Heme oxygenase--carbon monoxide signalling pathway as a physiological regulator of vascular smooth muscle cells.Acta Physiol Pharmacol Bulg. 2000;25(1):9-17. Acta Physiol Pharmacol Bulg. 2000. PMID: 11140191 Review.
-
Heme oxygenase-1 in growth control and its clinical application to vascular disease.J Cell Physiol. 2003 Jun;195(3):373-82. doi: 10.1002/jcp.10274. J Cell Physiol. 2003. PMID: 12704646 Review.
Cited by
-
Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs.World J Gastroenterol. 2022 Jan 21;28(3):275-289. doi: 10.3748/wjg.v28.i3.275. World J Gastroenterol. 2022. PMID: 35110950 Free PMC article.
-
Exhaled carbon monoxide and risk of metabolic syndrome and cardiovascular disease in the community.Circulation. 2010 Oct 12;122(15):1470-7. doi: 10.1161/CIRCULATIONAHA.110.941013. Epub 2010 Sep 27. Circulation. 2010. PMID: 20876437 Free PMC article.
-
Mechanisms of the vasorelaxing effects of CORM-3, a water-soluble carbon monoxide-releasing molecule: interactions with eNOS.Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386(3):185-96. doi: 10.1007/s00210-012-0829-9. Epub 2013 Jan 8. Naunyn Schmiedebergs Arch Pharmacol. 2013. PMID: 23296254
-
Carbon monoxide inhibits L-type Ca2+ channels via redox modulation of key cysteine residues by mitochondrial reactive oxygen species.J Biol Chem. 2008 Sep 5;283(36):24412-9. doi: 10.1074/jbc.M803037200. Epub 2008 Jul 1. J Biol Chem. 2008. PMID: 18596041 Free PMC article.
-
Novel therapies for cyclic GMP control of vascular smooth muscle growth.Am J Ther. 2008 Nov-Dec;15(6):551-64. doi: 10.1097/MJT.0b013e318140052f. Am J Ther. 2008. PMID: 19127140 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources